Cybin Inc.
March 13, 2024 - by Joey Ramson
Canadian biopharmaceutical company $CYBN, got granted the breakthrough therapy designation for its psychedelic-based experimental treatment, CYB003, used in the treatment of major depressive disorder this morning. The company also said it expects to raise $150 million in a private placement, with the proceeds being used to cover some of CYB003 Phase 3 costs.
